SIX •
Healthcare •
Biotechnology •
Quote as of 07/24/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeSIX
Market Capitalization1,508.56 mln
Float158 mln
Earnings Date04/28/2026
Piotroski F-Score
5
/ 9
Neutral
Beneish M-Score
-3.02
Reliable
1-Year Forecast
4.67
Downside risk
Relative Strength
52
/ 100
In line with market
Debt / Equity
-1.12
Negative equity
Dividend Yield
0.00%
No dividend
Business Description
Idorsia is a Swiss biopharmaceutical company focused on researching and bringing to market new medicines that address conditions with few or no existing treatment options, including sleep disorders, heart and immune system conditions, and rare diseases. Its leading product, QUVIVIQ, is an approved treatment for insomnia, while several other potential therapies are at various stages of clinical testing across areas such as skin conditions, neurological disorders, and organ injury. The company operates across multiple major markets, including the United States, Japan, China, and Europe. Founded in 2017 and based in Allschwil, Switzerland, Idorsia also works alongside partners such as Janssen Biotech and Viatris to develop and commercialize additional treatments.
